Stock Market Reviews

MDT (Medtronic plc) News

Get the latest news, insights, and market updates on MDT (Medtronic plc). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Stocks Fall Pre-Bell as Traders Await Key Inflation Report, Fed Meeting Minutes
  The benchmark US stock measures were tracking in the red before the opening bell Tuesday as traders
  Feb 17, 2026 - $MDT
• Pre-Markets in Red to Start Holiday Shortened Week
  Pre-Markets in Red to Start Holiday Shortened Week.
  Feb 17, 2026 - $MDT
• Pre-Markets Begins Shorter Week Slowly
  Empire State moderates and new earnings hit the tape for Tuesday morning.
  Feb 17, 2026 - $MDT
• Medtronic Reports $9B Q3 Revenue, 8.7% Growth, Reiterates FY26 Outlook
  Q3 non-GAAP EPS of $1.36 beats by $0.02; FY26 EPS guided to $5.62--$5.66, including $185M tariff impact.
  Feb 17, 2026 - $MDT
• Medtronic PLC (MDT) Q3 2026 Earnings Call Highlights: Strong Cardiovascular Growth and ...
  Medtronic PLC (MDT) reports robust revenue growth driven by cardiovascular advancements and strategic product launches, despite facing challenges in certain segments.
  Feb 17, 2026 - $MDT
• Medtronic (MDT) Q3 Earnings and Revenues Top Estimates
  Medtronic (MDT) delivered earnings and revenue surprises of +2.07% and +1.35%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?
  Feb 17, 2026 - $MDT
• Medtronic Maintains Full-Year Outlook; Beats Fiscal Third-Quarter Revenue Estimates
  Medtronic (MDT) affirmed its full-year outlook on Tuesday, while the medical device maker's revenue
  Feb 17, 2026 - $MDT
• Medtronic beats Q3 expectations with highest revenue growth in 10 quarters
  Investing.com -- Medtronic plc (NYSE: MDT) reported third quarter fiscal 2026 results that exceeded analyst expectations, with revenue reaching $9.0 billion, up 8.7% as reported and 6.0% on an organic basis compared to the same period last year.
  Feb 17, 2026 - $MDT
• Medtronic Antitrust Verdict Raises Questions Around Valuation And Future Risks
  Medtronic (NYSE:MDT) has been found liable for violating U.S. antitrust laws in the advanced bipolar devices market. A federal jury awarded more than US$381m in damages to Applied Medical in the case. The verdict centers on alleged anticompetitive practices affecting surgical device competition. For you as an investor, this case touches a core part of Medtronic's medical device portfolio and raises questions about how it competes in specialized procedure tools. The ruling comes at a time...
  Feb 17, 2026 - $MDT
• MDT Stock Up on Q3 Earnings and Revenue Beat, Margins Down
  Medtronic tops Q3 revenue and EPS estimates as Cardiovascular and Diabetes drive growth, but margin contraction tempers the upbeat quarter.
  Feb 17, 2026 - $MDT